Highly specific hybrid protein DARPin-mCherry for fluorescent visualization of cells overexpressing tumor marker HER2/neu
- 169 Downloads
Here we propose a simple and reliable approach for detection of the tumor marker HER2/neu using the targeting fluorescent hybrid protein DARPin-mCherry. As a targeting module, we used DARPin9-29, which is a member of a novel class of non-immunoglobulin targeting proteins that can highly selectively recognize the extracellular domain of the epidermal growth factor receptor HER2/neu. The red fluorescent protein mCherry was used as the detecting module. The hybrid protein DARPin-mCherry was prepared with high yield in a bacterial expression system and purified in one step by affinity chromatography. The purified protein is not prone to aggregation. The specificity of DARPin-mCherry binding with the HER2/neu tumor marker was demonstrated using confocal microscopy, flow cytofluorimetry, and surface plasmon resonance. The dissociation constant of the DARPin-mCherry protein complex with the HER2/neu receptor determined by surface plasmon resonance was calculated to be 4.5 nM. These characteristics of the hybrid protein DARPin-mCherry suggest it as a promising agent for immunofluorescent assay and an attractive alternative to antibodies and their fragments labeled with fluorescent dyes that are now used for this purpose.
Key wordsDARPin mCherry tumor marker HER2/neu
Unable to display preview. Download preview PDF.
- 17.Boersma, Y. L., Chao, G., Steiner, D., Wittrup, K. D., and Pluckthun, A. (2011) Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling, J. Biol. Chem., 286, 41273–41285.PubMedCentralPubMedCrossRefGoogle Scholar
- 18.Souied, E. H., Devin, F., Mauget-Faysse, M., Kolar, P., Wolf-Schnurrbusch, U., Framme, C., Gaucher, D., Querques, G., Stumpp, M. T., and Wolf, S. (2014) Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study, Am. J. Ophthalmol., DOI: 10.1016/j.ajo.2014.05.037.Google Scholar